Advanced Oncotherapy (LON:AVO) Releases Earnings Results, Misses Estimates By $0.93 EPS

Advanced Oncotherapy (LON:AVO) issued its earnings results on Monday. The company reported GBX (9.83) (($0.12)) EPS for the quarter, missing analysts’ consensus estimates of GBX (8.90) (($0.11)) by GBX (0.93) (($0.01)), Bloomberg Earnings reports.

Shares of LON AVO remained flat at $GBX 26 ($0.32) during trading hours on Wednesday. The company had a trading volume of 345,853 shares, compared to its average volume of 79,755. The stock has a fifty day moving average price of GBX 26.61 and a two-hundred day moving average price of GBX 32.04. Advanced Oncotherapy has a twelve month low of GBX 20 ($0.25) and a twelve month high of GBX 44.50 ($0.55). The company has a current ratio of 2.16, a quick ratio of 0.79 and a debt-to-equity ratio of 55.71. The company has a market capitalization of $79.66 million and a P/E ratio of -1.86.

Advanced Oncotherapy Company Profile

Advanced Oncotherapy PLC, together with its subsidiaries, focuses on providing radiotherapy systems for the treatment of cancer. The company operates through two segments, Proton Therapy and Healthcare Related Properties. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer.

Featured Article: What is intrinsic value?

Receive News & Ratings for Advanced Oncotherapy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Oncotherapy and related companies with MarketBeat.com's FREE daily email newsletter.